Patents by Inventor Lena Tagmose

Lena Tagmose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20220177557
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: August 11, 2021
    Publication date: June 9, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11111290
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10647762
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200109192
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 9, 2020
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
    Patent number: 10603310
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 31, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10487142
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: November 26, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use
    Patent number: 10472415
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: November 12, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjærgaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20190284265
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: April 1, 2019
    Publication date: September 19, 2019
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20190284266
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: April 1, 2019
    Publication date: September 19, 2019
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • 2-AMINO-6-(DIFLUOROMETHYL)-5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
    Publication number: 20190000823
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 3, 2019
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • 2-AMINO-3-FLUORO-3-(FLUOROMETHYL)-6-METHYL-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
    Publication number: 20180244645
    Abstract: The present invention provides compounds of Formula (I) for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula (I).
    Type: Application
    Filed: August 10, 2016
    Publication date: August 30, 2018
    Inventors: Karsten JUHL, Lena TAGMOSE, Mauro MARIGO
  • 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease
    Patent number: 10059669
    Abstract: The present invention is directed to compounds according to Formula (I) which compounds are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for 5 which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 28, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
    Patent number: 10058540
    Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 28, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • 2-AMINO-7A-PHENYL-3,4,4A,5,7,7A-HEXAHYDROFURO[3,4-B]PYRIDINES AS BACE1 INHIBITORS
    Publication number: 20180230160
    Abstract: Compounds of the Formula (I) are provided which compounds inhibitors of BACE1.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo, Ask Puschl
  • 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
    Patent number: 10045974
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 14, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • 6-AMINO-5-FLUORO-5-(FLUOROMETHYL)-2,3,4,5-TETRAHYDROPYRIDIN-2-YL-PHENYL-5-(METHOXY-D3)-PYRAZINE-2-CARBOXAMIDES AND FLUORINATED DERIVATIVES THEREOF AS BACE1 INHIBITORS
    Publication number: 20180186769
    Abstract: The invention provides amidine compounds of Formula I for the treatment of neurodegenerative or cognitive diseases, including Alzheimer's Disease.
    Type: Application
    Filed: December 20, 2017
    Publication date: July 5, 2018
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
    Patent number: 10011596
    Abstract: The present invention provides compounds of Formula I for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula I.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 3, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
    Patent number: 10004738
    Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive A? peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: June 26, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
    Publication number: 20180016330
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 18, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjærgaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • 2-Amino-5,5-Difluoro-6-(Fluoromethyl)-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors
    Publication number: 20170340618
    Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Application
    Filed: November 9, 2015
    Publication date: November 30, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo